TP53 and glioblastoma: Derivatives of pyridocarbazole and benzopyridoindole are other ATP-competitive CK2 inhibitors displaying in vitro and in vivo antitumoral activity in p53 mutant glioblastoma cells particularly resistant to drug-induced apoptosis [116].